Table 3.

Diagnostic methods and anticoagulation strategies for CTEPH in the included studies.

	Year	Diagnostic method	Anticoagulants	Treatment duration
C. Martinez	2018	NA	NA	NA
Carlos Aranda	2020	CT pulmonary angiography	Low molecular weight heparin, Vitamin K Antagonists	≥6 mo
Chih-Hsin Hsu	2019	right heart catheterization, V/Q scan	Low molecular weight heparin	≥6 mo
David Marti	2010	V/Q scan	Low molecular weight heparin, Vitamin K Antagonists	≥3 mo
F.A. Klok	2014	enhanced computed tomography CT, V/Q scan, CT pulmonary angiography	Low molecular weight heparin, Vitamin K Antagonists, Factor Xa inhibitor rivaroxaban	≥3 mo
Farid Rashidi	2020	CT pulmonary angiography, right heart catheterization, V/Q scan	Enoxaparin, warfarin	≥3 mo
Frederikus A. Klok	2010	CT pulmonary angiography, V/Q scan	Low molecular weight heparin, Vitamin K Antagonists	≥6 mo
Gudula J. A. M. Boon	2021	V/Q scan, right heart catheterization	NA	NA
Laurent Guérin	2014	V/Q scan	NA	NA
Suqiao Yang	2015	right heart catheterization, V/Q scan	Vitamin K Antagonists	≥6 mo
Vittorio Pengo	2004	CT pulmonary angiography, V/Q scan	Low molecular weight heparin	≥6 mo

CTEPH = chronic thromboembolic pulmonary hypertension.